ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights
Authors:
Open Access
- 7 August 2025
- journal article
- review article
- Published by Springer Nature in International Journal of Hematology
- Vol. 122 (3) , 327-340
Abstract
Clonal hematopoiesis (CH) is defined as the age-associated expansion of hematopoietic stem and progenitor cells harboring somatic mutations, most frequently in epigenetic regulators such as DNMT3A, TET2, and ASXL1. Although CH was initially recognized as a precursor to hematological malignancies, accumulating evidence has led to its broad recognition as a relevant factor in various age-related nonmalignant diseases, particularly those with inflammatory components, such as cardiovascular disease, autoimmune disorders, and solid tumors. Notably, the increased overall mortality associated with CH is primarily driven by cardiovascular complications rather than hematological malignancies. Among CH-associated genes, ASXL1 mutations are distinguished by their strong associations with adverse clinical outcomes and pro-inflammatory signatures. However, compared to TET2 and DNMT3A, the molecular and pathological implications of ASXL1-mutated CH remain underexplored. Recent studies have expanded the disease spectrum of ASXL1 mutations beyond hematological malignancies, implicating them in clonal expansion and systemic inflammation. This review aims to summarize the current epidemiological and experimental insights into ASXL1-mutated CH, focusing on its potential contributions to inflammation-associated diseases. By integrating clinical observations and emerging mechanistic data, we highlight the urgent need for deeper investigation into ASXL1-driven CH and its systemic consequences beyond hematological transformation.Keywords
Funding Information
- The University of Tokyo
This publication has 98 references indexed in Scilit:
- ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesNew England Journal of Medicine, 2011
- Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- The PHD finger: a versatile epigenome readerTrends in Biochemical Sciences, 2011
- Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUBNature, 2010
- Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemiaLeukemia, 2010
- Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemiaBlood, 2010
- Role of the polycomb protein EED in the propagation of repressive histone marksNature, 2009
- Methylation of Lysine 4 on Histone H3: Intricacy of Writing and Reading a Single Epigenetic MarkMolecular Cell, 2007
- A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11Gene, 2003